GlaxoSmithKline (GSK) Issues Quarterly Earnings Results

GlaxoSmithKline (LON:GSK) posted its earnings results on Wednesday. The company reported GBX 24.60 ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of GBX 24.30 ($0.34) by GBX 0.30 ($0.00), Bloomberg Earnings reports. GlaxoSmithKline had a return on equity of 348.10% and a net margin of 9.36%.

LON:GSK traded up GBX 24.60 ($0.34) during trading hours on Thursday, reaching GBX 1,436.80 ($20.04). The stock had a trading volume of 8,498,186 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($17.23) and a 12-month high of GBX 1,724.50 ($24.05).

The company also recently announced a dividend, which will be paid on Thursday, July 12th. Shareholders of record on Thursday, May 10th will be given a GBX 19 ($0.26) dividend. This represents a yield of 1.35%. The ex-dividend date of this dividend is Thursday, May 10th.

A number of research analysts have recently weighed in on the company. Berenberg Bank set a GBX 1,780 ($24.83) target price on GlaxoSmithKline and gave the company a “buy” rating in a report on Wednesday. UBS set a GBX 1,550 ($21.62) target price on GlaxoSmithKline and gave the company a “buy” rating in a report on Thursday, February 8th. Credit Suisse Group set a GBX 1,300 ($18.13) price target on GlaxoSmithKline and gave the stock a “neutral” rating in a report on Thursday, February 8th. Goldman Sachs set a GBX 1,750 ($24.41) price target on GlaxoSmithKline and gave the stock a “buy” rating in a report on Friday, March 2nd. Finally, Morgan Stanley set a GBX 1,400 ($19.53) price target on GlaxoSmithKline and gave the stock a “neutral” rating in a report on Wednesday, March 28th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of GBX 1,554.32 ($21.68).

In other GlaxoSmithKline news, insider Patrick Vallance sold 14,022 shares of the firm’s stock in a transaction on Monday, February 19th. The stock was sold at an average price of GBX 1,318 ($18.38), for a total value of £184,809.96 ($257,754.48). Also, insider Philip R. Hampton bought 3,028 shares of the firm’s stock in a transaction on Wednesday, April 25th. The stock was purchased at an average cost of GBX 1,445 ($20.15) per share, with a total value of £43,754.60 ($61,024.55). Over the last three months, insiders acquired 3,617 shares of company stock valued at $5,130,288 and sold 23,765 shares valued at $31,152,709.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$0.27 Earnings Per Share Expected for FNB Co.  This Quarter
$0.27 Earnings Per Share Expected for FNB Co. This Quarter
Bytom  Price Down 12.2% Over Last 7 Days
Bytom Price Down 12.2% Over Last 7 Days
DigixDAO 24 Hour Trading Volume Tops $1.59 Million
DigixDAO 24 Hour Trading Volume Tops $1.59 Million
Viuly  Price Hits $0.0070 on Major Exchanges
Viuly Price Hits $0.0070 on Major Exchanges
Superior Energy Services, Inc.  Expected to Post Earnings of -$0.22 Per Share
Superior Energy Services, Inc. Expected to Post Earnings of -$0.22 Per Share
Brokerages Anticipate Finish Line, Inc.  Will Post Quarterly Sales of $422.09 Million
Brokerages Anticipate Finish Line, Inc. Will Post Quarterly Sales of $422.09 Million


© 2006-2018 Ticker Report. Google+.